Actively Recruiting
Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer
Led by Ruijin Hospital · Updated on 2026-01-26
387
Participants Needed
5
Research Sites
254 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a multicenter, open-label, phase 3, randomized, non-inferiority study aimed to investigate the effect on disease-free survival of adjuvant chemotherapy with oxaliplatin plus S-1 compared with adjuvant chemotherapy with docetaxel plus S-1 after D2 gastrectomy in patients with stage III gastric cancer.
CONDITIONS
Official Title
Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 80 years old, male or female
- Histologically confirmed adenocarcinoma of the stomach or gastroesophageal junction
- Underwent standard D2 gastrectomy with complete tumor removal (R0 resection) and no prior systemic therapy
- Pathological stage IIIA, IIIB, or IIIC gastric cancer with Lauren classification
- No evidence of metastatic disease
- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1
- Adequate organ function: ANC ≥1.5x10^9/L, white blood count ≥3.5x10^9/L, platelets ≥75x10^9/L, hemoglobin ≥80 g/L, ALT/AST ≤2.5 times upper limit of normal (≤5 times if liver metastasis), serum bilirubin ≤1.5 times upper limit, serum creatinine ≤1.5 times upper limit
- Women of childbearing potential must use contraception starting at least one month before screening and throughout the study and specified post-study period
- Signed informed consent and willingness to follow study procedures
You will not qualify if you...
- Presence of other primary cancers except cured skin tumors or cervical carcinoma in situ
- Severe complications likely to limit survival to less than 5 years
- Uncontrolled comorbidities such as infections, hypertension, diabetes, or heart disease
- Allergy to study medications
- Conditions affecting ability to take oral medication such as bowel obstruction
- Organ function inadequate to tolerate study treatment
- Any other condition making the patient unsuitable for the study as judged by investigators
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
Yuebei People's Hospital
Shaoguan, Guandong, China
Not Yet Recruiting
2
Fudan University Shanghai Cancer Center
Shanghai, China
Not Yet Recruiting
3
Renji Hospital
Shanghai, China
Not Yet Recruiting
4
Ruijin Hospital
Shanghai, China
Actively Recruiting
5
Shanghai Tenth People's Hospital
Shanghai, China
Not Yet Recruiting
Research Team
C
Chenfei Zhou, MD, Ph.D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here